Table 2

CCND1.COMT interaction in breast cancer cases from Ontario and Finland populations.

ONTARIO

FINLAND


Combined Enzymatic Activity

Combined Genotype

Controls N (%)

Cases N (%)

OR

CI

Controls N (%)

Cases N (%)

OR

CI


CCND1Low/COMTLow

GGAA

73 (10.2)

74 (6.1)

1.0

-

51 (9.4)

52 (7.4)

1.0

-

CCND1Low/COMTMedium, CCND1Low/COMTHigh, CCND1Medium/COMTMedium, CCND1Medium COMTLow, CCND1Medium COMTHigh, CCND1High/COMTLow

GGAG, GGGG, AGAG, AGAA, AGGG, AAAA

534 (74.4)

897 (73.6)

1.66

1.18–2.33

416 (76.6)

515 (73.4)

1.21

0.81–1.83

CCND1High/COMTMedium, CCND1High/COMTHigh

AAAG, AAGG

107 (14.9)

240 (19.8)

2.22

1.49–3.28

76 (14)

134 (19.1)

1.73

1.08–2.78

Total

714

1211

543

701

Trend Test

p = 0.00013

p = 0.012


Onay et al. BMC Cancer 2008 8:6   doi:10.1186/1471-2407-8-6

Open Data